Ligand binding to I2 imidazoline receptor: The role of lipophilicity in quantitative structure-activity relationship models

Bioorganic and Medicinal Chemistry

Volumn 6, Issue 12, 1998, Pages 2245-2260

  Pigini, M ^a   Bousquet, P ^b   Brasili, L ^c   Carrieri, A ^d   Cavagna, R ^b   Dontenwill, M ^b   Gentili, F ^a   Giannella, M ^a   Leonetti, F ^d   Piergentili, A ^a   Quaglia, W ^a   Carotti, A ^d  

^a UNIVERSITY OF CAMERINO   (Italy)

^b UNIVERSITÉ DE STRASBOURG   (France)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

Comparative molecular field analysis; Imidazoline receptor; Pharmacophore model; Quantitative structure activity relationships

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; CIRAZOLINE; CLONIDINE; IDAZOXAN; IMIDAZOLINE DERIVATIVE; IMIDAZOLINE RECEPTOR; TRACIZOLINE; UNCLASSIFIED DRUG; ALPHA 2 ADRENERGIC RECEPTOR; DRUG RECEPTOR; IMIDAZOLE DERIVATIVE; IMIDAZOLINE RECEPTORS; LIGAND;

ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG DEVELOPMENT; DRUG SYNTHESIS; IN VITRO STUDY; KIDNEY; LIGAND BINDING; LIPOPHILICITY; MODEL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PKA; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RABBIT; RAT; STATISTICS; ANIMAL; BINDING COMPETITION; BRAIN CORTEX; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; CONFORMATION; DRUG EFFECT; ELECTRICITY; KINETICS; METABOLISM; RADIOASSAY; REGRESSION ANALYSIS; SOLUBILITY; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ANIMALS; BINDING, COMPETITIVE; CEREBRAL CORTEX; CLONIDINE; ELECTROSTATICS; IDAZOXAN; IMIDAZOLES; KIDNEY; KINETICS; LIGANDS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; RABBITS; RADIOLIGAND ASSAY; RATS; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, DRUG; REGRESSION ANALYSIS; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032217337     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-0896(98)80005-9     Document Type: Article

References (62)

1. Bousquet, P. Neurochem. Int. 1997, 30, 3.
2. The Imidazoline Receptor: Pharmacology, Functions, Ligands, and Relevance to Biology and Medicine; Reis, D. J.; Bousquet, P.; Parini, A., Eds.; Ann. N. Y. Acad. Sci. 1995, Vol. 763.
3. Molderings, G. J. Drugs of the Future, 1997, 22, 757.
4. Michel, M. C.; Ernsberger, P. Trends Pharmacol. Sci. 1992, 13, 369.
5. Tesson, F.; Prip-Buus, C.; Lenoine, A.; Pegorier, J. P.; Parini, A. J. Biol. Chem. 1991, 266, 155.
6. van Zwieten, P. A. J. Hypertens. 1997, 15, 117 and S3.
7. Chu, T. C.; Socci, R. R.; Ogidigben, M. J.; Potter, D. E. J. Ocul. Pharmacol. Therap. 1997, 13, 489.
8. Olmos, G.; Alemany, R.; Escriba, P. V.; Garcia-Sevilla, J. A. Br. J. Pharmacol. 1994, 111, 997.
9. LeBrigand, L.; Virsolvy, A.; Peyrollier, K.; Manechez, D.; Godfroid, J. J.; Guardiola Lemaitre, B.; Bataille, D. Brit. J. Pharmacol. 1997, 122, 786.
10. Molderings, G. J.; Donecker, K.; Burian, M.; Simon, W. A.; Schroeder, D. W., Göthert, M. J. Pharmacol. Exp. Ther. 1998, 285, 170.
11. Hohage, H.; Hess, K.; Jahl, C.; Greven, J.; Schlatter, E. Clin. Nephrol. 1997, 48, 346.
12. Ohara-Imaizumi, M.; Kumakura, K. Cell. Mol. Neurobiol. 1992, 12, 273.
13. Molderings, G. J.; Schmidt, K.; Bönisch, H.; Göthert, M. Naunyn-Schmied Arch. Pharmacol. 1995, 354, 245.
14. Nutt, D. J.; French, N.; Handley, S.; Hudson, A.; Husband, S.; Jackson, H.; Jordan, S.; Lalies, M. D.; Lewis, J.; Lione, L.; Mallard, N.; Prat, J. Ann. N. Y. Acad. Sci. 1995, 763, 125.
15. Musgrave, I. F.; Krautwarst, D.; Schultz, G. Clin. Exp. Pharmacol. Physiol. 1996, 23, 990.
16. Drnsbezrger, P.; Friedman, J. E.; Koletsky, R. J. J. Hypertension 1997, 15, S9.
17. Brasili, L.; Pigini, M.; Bousquet, P.; Carotti, A.; Dontenwill, M.; Giannella, M.; Moriconi, R.; Piergentili, A.; Quaglia, W.; Tayebati, K. S. In Perspective in Receptor Research; Giardinà, D.; Piergentili, A.; Pigini, M., Eds.; Elsevier: Amsterdam, 1996; 361-373.
18. Pigini, M.; Bousquet, P.; Carotti, A.; Dontenwill, M.; Giannella, M.; Moriconi, R.; Piergentili, A.; Quaglia, W.; Tayebati, S. K.; Brasili, L. Bioorg. Med. Chem. 1997, 5, 833.
19. Carrieri, A.; Brasili, L.; Leonetti, F.; Pigini M.; Giannella, M.; Bousquet, P.; Carotti, A. Bioorg. Med. Chem. 1997, 5, 843.
20. Kubinyi, H. QSAR: Hansch Analysis and Related Approaches, VHC: Weinheim, 1993.
21. Cramer, R. D.; Patterson, D. E.; Bunce, J. D. J. Am. Chem. Soc. 1988, 110, 5959.
22. Kneubühler, S.; Thull, U.; Altomare, C.; Carta, V.; Gaillard, P.; Carrupt, P.-A.; Carotti, A.; Testa, B. J. Med. Chem. 1995, 38, 3874.
23. Carrieri, A.; Altomare, C.; Barreca, M. L.; Contento, A.; Carotti, A.; Hansch, C. Il Farmaco, 1994, 49, 573.
24. Altomare, C.; Carotti, A.; Cellamare, S.; Carrupt, P.-A.; Testa, B. Chirality 1993, 5, 527.
25. Greco, G.; Novellino, E.; Silipo, C.; Vittoria, A. Quant. Struct. -Act. Relat. 1992, 11, 461.
26. Debnath, A. K.; Hansch, C.; Kim, H. K.; Martin, Y. C. J. Med. Chem. 1993, 36, 1007.
27. C-Log P Mac vers. 2. 0, 1996, Biobyte Corp., Claremont, CA, USA.
28. Hansch, C.; Leo, A.; Hoeckman, D. Exploring QSAR, ACS, Washington, 1995, vol 2.
29. Carotti, A.; Altomare, C. Chim. & Ind., 1995, 77, 13 and references therein.
30. Selassie, C. D.; Klein, T. E. In 3D QSAR in Drug Design: Theory, Methods and Applications; Kubinyi, H. Ed.; Escom: Leiden, 1993; pp 257-275.
31. 30 pp 443-485.
32. Dunn, III W. J.; Wold, S.; Edlund, U.; Helberg, S. Quant. Struct. -Act. Relat. 1984, 3, 131.
33. 30 pp 523-549.
34. Cramer, III R. D; Bunce, J. D.; Patterson, D. E. Quant. Struct. -Act. Relat. 1988, 7, 18.
35. 30 pp 661-696.
36. Gaillard, P.; Carrupt, P.-A.; Testa, B.; Boudon, A. J. Comput. -Aided Mol. Des. 1994, 8, 83.
37. Gaillard, P.; Carrupt, P.-A.; Testa, B.; Schambel, P. J. Med. Chem. 1996, 39, 126.
38. Testa, B.; Carrupt, P.-A.; Gaillard, P.; Billois, F.; Weber, P. Pharm. Res. 1996, 13, 126.
39. Stewart, J. J. P. J. Comput. -Aided Mol. Des. 1990, 4, 1.
40. Wold, S.; Eriksson, L. In Chemometric Methods in Molecular Design; van de Waterbeemd, H., Ed.; VCH: Weinheim, 1996, pp 309-318.
41. 30 pp 583-618.
42. 40 pp 195-218.
43. Testa, B.; Carrupt, P.-A.; Gaillard, P.; Tsai, R. S. Intramolecular Interactions Encoded in Lipophilicity. In Lipophilicity in Drug Action and Toxicology; Pliska, V.; Testa, B.; van der Waterbeemd, H., Eds.; VCH: Weinheim, 1997, pp 49-71.
44. 43 pp 195-217.
45. McFarland, J. W.; Howes, Jr. H. L. J. Med. Chem. 1972, 15, 365.
46. Shvekhgeimer, G. A.; Gorbatov, E. I.; Tyurin, V. D. Zh. Org. Khim. 1971, 7, 815; Chem. Abstr. 1971, 75, 35881p.
47. Shvekhgeimer, G. A.; Gorbatov, E. I.; Tyurin, V. D. Zh. Org. Khim. 1971, 7, 815; Chem. Abstr. 1971, 75, 35881p.
48. Chas. Pfizer & Co., Inc. Neth. Appl. 6, 607, 037; Chem. Abstr. 1968, 68, 49640b.
49. Chas. Pfizer & Co., Inc. Neth. Appl. 6, 607, 037; Chem. Abstr. 1968, 68, 49640b.
50. McFarland, J. W.; Conover, L. H.; Howes, Jr. H. L.; Lynch, J. E.; Chisholm, D. R.; Austin, W. C.; Cornwell, R. L.; Danilewicz, J. C.; Courtney, W.; Morgan, D. H. J. Med. Chem. 1969, 12, 1066.
51. Pagani, G.; Caccialanza, G.; Montanari, L. Il Farmaco-Ed. Sci. 1973, 28, 231 and ref. therein.
52. Kolsaker, P.; Ellingsen, P. O. Acta Chem. Scand. B 1979, 33, 138.
53. Kolsaker, P.; Bailey, P. S. Acta Chem. Scand. 1967, 21, 537.
54. de la Mare, P. B. D.; Wilson, M. A.; Rosser, M. J. J. Chem. Soc., Perkin Trans. 2 1973, 1480.
55. Sarbbani, S. G. S. J. Chem. Soc. 1928, 54.
56. Adamson, D. W. J. Chem. Soc. 1950, 885 and ref. therein.
57. House, H. O.; Melillo, D. G.; Sauter, F. J. J. Org. Chem. 1973, 38, 741.
58. Ardakani, M. A.; Smalley, R. K.; Smith, R. H. J. Chem. Soc., Perkin Trans. 1 1983, 2501.
59. Baker, J. W.; Hopkins, H. B. J. Chem. Soc. 1949, 1089.
60. van de Waterbeemd, H.; Testa, B. Advances in Drug Research; Testa, B., Ed.; Academic Press: New York, 1987, vol. 16, pp 85-225.
61. MOPAC 6. O is available from QCPE (506).
62. Clark, M.; Cramer, R. D.; Van Opdenbasch, N. J. Comput. Chem. 1989, 10, 982.